Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (21-30 of 247) with videos related to

Pageof 25
Sort By:
Cancer Biology & Therapy|September 22, 2010
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumorsJens Rüter, Scott J Antonia, Howard A Burris, et al.
Clinical Breast Cancer|July 7, 2011
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancerHoward A Burris, Jay Tibbitts, Scott N Holden, et al.
Breast Cancer Research and Treatment|November 7, 2014
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trialDenise A Yardley, Eric Raefsky, John D Hainsworth, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignanciesSuzanne F Jones, David R Spigel, Denise A Yardley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Cancer Medicine|April 28, 2015
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsinPhilip T Sager, Barbara Balser, Julie Wolfson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
Phase II trial of vinflunine in relapsed small cell lung cancerDavid R Spigel, John D Hainsworth, Cassie M Lane, et al.
The Oncologist|March 29, 2005
Phase II trial of oral rubitecan in previously treated pancreatic cancer patientsHoward A Burris, Saul Rivkin, Robert Reynolds, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Pageof 25

Showing results (21-30 of 247) with videos related to

Sort By:
Pageof 25
Cancer Biology & Therapy|September 22, 2010
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumorsJens Rüter, Scott J Antonia, Howard A Burris, et al.
Clinical Breast Cancer|July 7, 2011
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancerHoward A Burris, Jay Tibbitts, Scott N Holden, et al.
Breast Cancer Research and Treatment|November 7, 2014
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trialDenise A Yardley, Eric Raefsky, John D Hainsworth, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignanciesSuzanne F Jones, David R Spigel, Denise A Yardley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Cancer Medicine|April 28, 2015
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsinPhilip T Sager, Barbara Balser, Julie Wolfson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
Phase II trial of vinflunine in relapsed small cell lung cancerDavid R Spigel, John D Hainsworth, Cassie M Lane, et al.
The Oncologist|March 29, 2005
Phase II trial of oral rubitecan in previously treated pancreatic cancer patientsHoward A Burris, Saul Rivkin, Robert Reynolds, et al.
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
The Oncologist|May 2, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesMelissa L Johnson, Manish R Patel, Raid Aljumaily, et al.
Pageof 25